RobertZOrlowskiMDPhD

PubMed

• Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.
  Luz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, Minghao Dang, Amishi Vora
  Cell Reports. Medicine. 2025-01-20
• Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
  Philippe Moreau, Thierry Facon, Saad Z Usmani, Nizar Bahlis, Noopur Raje
  Leukemia. 2025-01-15
• 1 citations
  Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.
  Rahul Banerjee, Rachael Sexton, Andrew J Cowan, Aaron S Rosenberg, Sikander Ailawadhi
  Blood. 2025-01-02

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
• Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191  
  Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research

Abstracts/Posters

• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all